Live Breaking News & Updates on Clinical

Stay informed with the latest breaking news from Clinical on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Clinical and stay connected to the pulse of your community

Cerevel undersell? Bombshell Parkinson's phase III with tavapadon

Cerevel Therapeutics Inc.’s positive results from the long-shot pivotal phase III Tempo-3 trial with tavapadon – the first D1/D5 receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease – added gravy to the $8.7 billion takeover by Abbvie Inc., disclosed late last year. The buyout’s centerpiece was the late-stage asset emraclidine, a positive allosteric modulator of the muscarinic M4 receptor, touted as a potential best-in-class, next-generation antipsychotic for schizophrenia, which strikes more than 5 million people in the G7 (U.S., France, Germany, Italy, Spain, U.K. and Japan).

Italy , France , Germany , Japan , Spain , Cerevel-therapeutics-inc , Abbvie-inc , Cerevel-therapeutics , Cerevel-therapeutics-inc- , Tavapadon , Parkinsons-disease

GP crisis: Katikati Medical Centre weighs in on workforce and funding concerns

Wait times for an appointment at Katikati Medical Centre (KMC) can be weeks long and while a new doctor should help the situation, the centre’s clinical...

Australia , Katikati , New-zealand-general- , New-zealand , Martin-hefford , Vicky-jones , Katikati-medical-centre , Health-new-zealand , Katikati-medical , New-zealand-te-whatu-ora , Gp , Crisis

Effector stock wilts as phase II cancer data disappoint

Top-line data from the phase II Kickstart study of Effector Therapeutics Inc.’s tomivosertib as a frontline treatment of non-small-cell lung cancer failed to produce data strong enough to continue development in the indication. The company has decided to halt the study, move ahead with a separate, investigator-sponsored study of tomivosertib in acute myeloid leukemia and focus on another drug in its pipeline for treating breast cancer.

Effector-therapeutics-inc , Nasdaq , Effector-therapeutics , Bioworld , Effector-therapeutics-inc- , Tomivosertib , Non-small-cell-lung-cancer , Clinical , Cancer , Merck-amp-co-inc- , Acute-myeloid-leukemia

The little-known bacteria behind the rising rates of cancer in under 50s

Last year, speakers at the annual American Society of Clinical Oncology meeting – the most eminent cancer conference in the world – came with a dire warning.

United-states , London , City-of , United-kingdom , Manchester , Belfast , American , Tim-obrien , Meera-patel , Dimitra-lamprinaki , Andrew-beggs , University-of-birmingham

Global eClinical Solutions Market Expected to Reach USD

Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The

Dublin , Ireland , Development-phase , Clinical-solutions , Clinical-solutions-market , Oracle , Watson-health , Contract-research-organizations-cros , Omnicomm-systems-inc , Medidata-solution-inc , Anju-software-inc

Dimerix raises AU$20M on positive phase III kidney disease data

Dimerix Ltd. announced a AU$20 million ($US13.22 million) capital raise following the news that its lead candidate, DMX-200, was successful in a prespecified interim analysis of the efficacy endpoint in its pivotal phase III trial in focal segmental glomerulosclerosis, a rare kidney disease.

Dimerix-ltd , Dimerix-ltd- , Dmx-200 , Focal-segmental-glomerulosclerosis , Kidney-disease , Proteinuria , Propagermanium , Bioworld , Bioworld-asia , Financings , Asia-pacific

Ironwood's apraglutide wins in short bowel but CIC questioned

Positive phase III data from Ironwood Pharmaceuticals Inc. with once-weekly glucagon-like peptide-2 analogue apraglutide failed to impress Wall Street, and shares of the Boston-based firm (NASDAQ:IRWD) closed Feb. 29 at $9.43, down $5.69, or 37.6%. The experiment called Stars tested apraglutide to reduce parenteral support in adults with short bowel syndrome with intestinal failure. Rare and severe, the condition affects about 18,000 adults in the U.S., Europe and Japan. Based on the latest data, Ironwood plans to submit an NDA to the U.S. FDA and other regulatory filings.

Boston , Massachusetts , United-states , Japan , Nasdaq , Ironwood-pharmaceuticals-inc , Ironwood-pharmaceuticals , Wall-street , Ironwood-pharmaceuticals-inc- , Apraglutide , Short-bowel-syndrome

Me-two drug? Viking mid-stage trial wins with GLP-1/GIP bid

The enticing prospect – and proven worth – of dually agonizing the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors gained more evidence in a big way from Viking Therapeutics Inc. with VK-2735 in a phase II weight loss study. Shares of San Diego-based Viking Therapeutics Inc. (NASDAQ:VKTX) closed Feb. 27 at $85.05, up $46.57, or 121%, as investors learned that the drug achieved the primary and all secondary endpoints in the phase II study called Venture, with significant body-weight drops at all doses compared to placebo.

Nasdaq , San-viking-therapeutics-inc , Therapeutics-inc , Viking-therapeutics , San-diego-based-viking-therapeutics , Viking-therapeutics-inc- , Vk-2735 , Glp-1 , Gip , Bioworld , Clinical

BEYOND CHEMO AND CLINICAL TRIALS

societyBreast cancer, a pervasive global health concern, is increasingly making its presence felt among young women in the subcontinent. While traditionally perceived as a disease affecting older age groups, recent trends point to a disturbing rise...

New-delhi , Delhi , India , Karachi , Sindh , Pakistan , Dhaka , Bangladesh , Sri-lanka , Nepal , Sara-danial , World-health-organization

What is Informed Consent?

Informed consent represents one of the most important ethical aspects of clinical treatments and scientific research involving humans.

Greece , United-states , United-kingdom , America , Satyanarayana-rao , Pressmaster-shutterstock , Intj-environ-res-public-health , Oxford-university , Johns-hopkins-university , Oxford-university-press , Silent-world , Johns-hopkins-university-press